Xu, C-F
Johnson, T
Garcia-Donas, J
Choueiri, T K
Sternberg, C N
Davis, I D
Bing, N
Deen, K C
Xue, Z
McCann, L
Esteban, E
Whittaker, J C
Spraggs, C F
RodrÃguez-Antona, C
Pandite, L N
Motzer, R J
Article History
Received: 12 November 2014
Revised: 15 January 2015
Accepted: 27 January 2015
First Online: 19 February 2015
Competing interests
: CFX, TJ, ZX, LM, JCW, CFS, and LNP are employees and stockholders of GlaxoSmithKline. NB and KCD were GlaxoSmithKline employees at the time of this study. JGD has received honoraria from GlaxoSmithKline, Pfizer, Novartis, and Bayer. CNS has received honoraria from GlaxoSmithKline, Pfizer, Novartis, and Bayer. IDD has been an advisory board member or chair for GlaxoSmithKline, Pfizer, Novartis, Janssen, Medivation, Sanofi, Bayer, Astellas, Ipsen, and Bristol-Myers Squibb, but all honoraria were directly donated to ANZUP Cancer Trials Group. TKC has received consultant compensation from GlaxoSmithKline, Pfizer, AVEO, Novartis, Genentech, Bayer, and Onyx. EE has been an advisory board member for GlaxoSmithKline, Pfizer, Novartis, and Bayer, but all honoraria were directly donated to UNDESO (foundation for the development of oncology research). RJM reports grants to his institution from GlaxoSmithKline, Pfizer, Novartis, and AVEO Oncology; he has received compensation from GlaxoSmithKline for travel and consultant compensation from Pfizer and Genentech. CR-A declares that she has no conflicts of interest.